Vital

Peptides

NAD+ Injection Dosage: FDA Status, Studies, and Unit Math

NAD+ injection dosage explained without guesswork: NAD+ is not an FDA-approved drug for injection, what the small human studies used, why injections can hurt, and how to convert a 100 mg/mL vial to syringe units.

Last reviewed

The Vital angle

Vital works out the draw volume as the amount divided by the vial concentration, and shows it in U-100 units with the mL next to it. Its reconstitution calculator accepts vial masses up to 1,500 mg, warns when a draw is more than a 1 mL syringe holds, and each dose log keeps the unit, injection site, lot number, and symptoms such as site pain.

NAD+ injection dosage: the short answer

There is no FDA-approved NAD+ injection dosage. NAD+ is not an approved drug for injection for energy, aging, weight, or any other use, so no label gives a dose or a frequency. The amounts that clinics and sellers list come from their own practice, not from outcome trials.

The human data are small. One blinded pilot trial gave 100 mg of NAD+ under the skin once daily for three days to six people, and it was posted as a preprint that is not peer reviewed. Other studies used intravenous infusions. None of them tested whether NAD+ injections improve a health outcome.

This guide explains the regulatory status, what those studies used, why injections can hurt, and how unit math works for a vial such as 100 mg/mL. It does not recommend a dose, a schedule, or a protocol. Ask the prescriber who gave you the vial.

What NAD+ is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that every cell uses in energy reactions. It is not a peptide, but it is sold next to peptides and drawn into the same insulin syringes. Some tissues have less NAD+ with age, which led to interest in raising it with oral precursors, infusions, or injections.

Two related compounds cause confusion:

  • NAD+ is the coenzyme itself.
  • NR (nicotinamide riboside) is a precursor that the body turns into NAD+. It is sold as an oral supplement, and one company also tests it as an injection.

A study of NR does not tell you about an NAD+ vial, and the reverse is also true.

NAD+ regulatory status

NAD+ has a different status from most peptides on this site:

  1. Not an approved drug. No FDA label covers injected NAD+ for any use.
  2. Compounding. On the FDA list of substances nominated for pharmacy compounding, updated May 14, 2026, "Nicotinamide Adenine Dinucleotide (NAD)" is in Category 1, "Bulk Drug Substances Under Evaluation." Under its interim policy, the FDA does not intend to act against a pharmacy that compounds a Category 1 substance if certain conditions are met. That is a decision about enforcement while the FDA reviews the substance. It is not an approval and not a finding of safety.
  3. Supplements. Oral precursors such as NR are sold as supplements, which do not go through FDA drug approval.

A vial from a licensed pharmacy with a prescription is a different product from a vial sold online for "research." Check the pharmacy, the lot number, and the expiration date. See peptide catalog source checks.

What the human studies used

The table lists the studies in people that we found, as of November 20, 2026. The doses are what each study used. They are not recommendations.

Study Route What it used What it measured
2019 pilot, Frontiers in Aging Neuroscience Intravenous NAD+ at 3 μmol per minute for 6 hours Blood and urine NAD+ levels
2026 retrospective review, Frontiers in Aging Intravenous 500 mg NAD+ or NR daily for 4 days Tolerability and lab tests
2026 preprint, Trial 1 (company-funded) Subcutaneous, intramuscular, intravenous 100 mg NAD+, NR, or placebo in 2 mL, once daily for 3 days Safety and injection experience

The 2019 pilot found that plasma NAD+ did not change for the first 2 hours of the infusion, which suggests that the body clears infused NAD+ from the blood quickly. In the 2026 review, NAD+ infusions took 97 minutes on average versus 37 minutes for NR. The authors linked this to moderate to severe stomach symptoms, a faster heart rate, and chest pressure during NAD+ infusions.

The 2026 preprint comes from ChromaDex, a company that sells NR, and it has not had peer review. Trial 1 had nine small groups, and the subcutaneous NAD+ group had six people. The authors report that the injections caused some discomfort but no worrying safety signals. A trial of this size cannot show that a dose is safe or that it works.

NAD+ 100 mg/mL units: the math

Many NAD+ vials are sold as a liquid with a printed strength, such as 100 mg/mL, or as powder that you mix with water. On a U-100 syringe, 1 unit is 0.01 mL. At 100 mg/mL, that makes 1 unit equal to 1 mg. This is a coincidence of that strength, not a general rule.

The steps are the same for any vial:

  1. Concentration (mg per mL) = mg in the vial ÷ mL of liquid.
  2. Volume (mL) = amount ÷ concentration.
  3. Units on a U-100 syringe = volume in mL × 100.

The numbers below are hypothetical round numbers that show the method. They are not doses.

Vial strength (hypothetical) Math amount 25 mg Math amount 50 mg Math amount 100 mg
100 mg/mL 0.25 mL, 25 units 0.50 mL, 50 units 1.00 mL, 100 units
200 mg/mL 0.125 mL, 12.5 units 0.25 mL, 25 units 0.50 mL, 50 units
50 mg/mL 0.50 mL, 50 units 1.00 mL, 100 units 2.00 mL, more than one syringe

Read the label for both the total and the strength. A vial printed "500 mg / 5 mL" is 100 mg/mL, not 500 mg/mL. The 2026 preprint dissolved 100 mg in 2 mL, which is 50 mg/mL and a 2 mL injection, twice what a 1 mL U-100 syringe holds. Confirm every draw with your prescriber or pharmacist, in mL and in units, before you inject.

The free peptide calculator does this math for powder vials. For reading the printed strength, see how to read a peptide vial label and how to read an insulin syringe for peptides.

NAD+ injection pain

Pain is a common complaint with NAD+ injections, and the studies support that it is real. In the 2026 preprint, pain and discomfort were the most common experiences across all products and routes, and people described burning and stinging. In its second trial, which used NR rather than NAD+, 45.9% of participants reported pain more than two minutes after the injection, and flushing or a heat sensation was reported only with injections under the skin.

Volume is one factor. A large volume under the skin stretches the tissue more than a small one. If injections hurt more than you expect, or the pain lasts, ask your prescriber or pharmacist. Do not change the strength, the volume, or the speed on your own. For skin reactions that look wrong, see peptide injection site reaction.

NAD+ injection frequency

No label or outcome trial sets a frequency for NAD+ injections. The 2026 preprint gave injections once daily for three days and then stopped. A separate registered trial, NCT07251608, tests NR injections three times a week for about 90 days in its subcutaneous groups, but NR is a different molecule. A schedule from a clinic is that clinic's choice, and you can ask what evidence supports it.

Logging NAD+ in Vital

Vital does the volume math the same way for any vial: the draw in mL is the amount divided by the concentration, and units are mL times 100 on the U-100 scale. The reconstitution calculator accepts vial masses up to 1,500 mg, so large NAD+ vials fit. If a draw is more than a 1 mL syringe holds, Vital shows a warning, which matters for the large volumes in the table above.

Each dose log keeps the unit you used, such as mg or mL, plus the injection site, the lot number, the expiration date, and any symptoms with a severity, such as pain at the site. The Vital peptide directory lists NAD+ as not FDA-approved, with a safety note that IV infusions need medical supervision. You can set a reminder schedule that matches what your clinician gave you, and the injection site rotation chart helps you vary sites.

Warning signs and when to get care

Get emergency care for chest pain, trouble breathing, or swelling of the face, lips, tongue, or throat. Get medical care soon for any of these signs:

  • A racing or irregular heartbeat, or fainting.
  • A hot, red, spreading, or very painful injection site, or pus.
  • Fever or chills after an injection.
  • Vomiting that stops you from keeping fluids down.

If you think you injected much more than intended, call your clinician or Poison Help at 1-800-222-1222. For how NAD+ compares with MOTS-c and SS-31, see MOTS-c vs SS-31 vs NAD+.


ChromaDex is named only as the funder of a preprint. Vital is independent and not affiliated with these companies.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Clinic or seller dosing charts

    No FDA label gives an NAD+ injection dose or frequency, and no outcome trial supports one. These charts reflect each seller's own practice.

  • Reading the total as the strength

    A vial printed 500 mg / 5 mL is 100 mg/mL. Reading 500 mg as the strength per mL gives a draw that is 5 times too small, and the reverse error gives 5 times too much.

  • Large volumes under the skin

    At 50 mg/mL, 100 mg is 2 mL, twice what a 1 mL U-100 syringe holds. Large volumes also stretch the tissue, which can add to pain.

  • Fast IV infusions

    A 2026 review of IV NAD+ reported moderate to severe stomach symptoms, a faster heart rate, and chest pressure during infusions, which made NAD+ infusions take longer than NR infusions.

  • Confusing NAD+ with NR

    Nicotinamide riboside is a precursor, not NAD+. Study results and schedules for NR injections do not apply to an NAD+ vial.

Frequently asked questions

  • There is no FDA-approved NAD+ injection dosage. NAD+ is not an approved drug for injection, and no outcome trial supports a dose. One small preprint trial gave 100 mg under the skin once daily for three days to six people. Ask the prescriber who gave you the vial.

  • At 100 mg/mL, 100 mg is 1.00 mL, which is 100 units on a U-100 syringe. At that strength, 1 unit equals 1 mg. This is math, not a dose. Confirm any draw with your prescriber or pharmacist.

  • Pain and discomfort were the most common experiences in a 2026 injection preprint, and people described burning and stinging. A large volume under the skin can add to it. If pain is strong or lasts, ask your prescriber, and do not change the strength or volume on your own.

  • No label or outcome trial sets a frequency. The 2026 preprint gave injections once daily for three days only. A clinic schedule is that clinic's choice, so ask what evidence supports it.

  • No. Injected NAD+ is not an FDA-approved drug for any use. NAD is in Category 1, under evaluation, on the FDA list of substances nominated for pharmacy compounding, which is not an approval.

  • No. The routes deliver the drug differently, and most human data are for IV infusions. A 2019 pilot found that plasma NAD+ did not change for the first 2 hours of an infusion, which suggests fast clearance from the blood.

Sources

  1. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) · U.S. Food and Drug Administration
  2. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act · U.S. Food and Drug Administration
  3. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ · NIH / NCBI (Frontiers in Aging Neuroscience, 2019)
  4. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting · NIH / NCBI (Frontiers in Aging, 2026)
  5. Preliminary Safety Analysis of Two Pilot Clinical Trials Involving Injections of Niagen, Nicotinamide Riboside Chloride (preprint) · medRxiv
  6. Randomized, Open-Label, Safety Pilot Study of Multiple Subcutaneous and Intramuscular Injections of Niagen Plus (NCT07251608) · ClinicalTrials.gov, U.S. National Library of Medicine

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.